21.2 C
New York
Tuesday, June 9, 2026

Tag: evaluation

Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation

Three certificates issued by Bureau Veritas support application in SOLAS-regulated marine environments across global, EU-flagged, and UK-flagged vessels.MINNETONKA, Minn., June 9, 2026 /PRNewswire/ --...

Mission Produce® Announces Fiscal 2026 Second Quarter Financial Results

Acquisition of Calavo Growers completed May 28, 2026

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

No Deposit Bonus Casinos for Real Money 2026: All iGaming Experts Reveal Casinos with Free Spins Bonuses

Vancouver, Canada, June 08, 2026 (GLOBE NEWSWIRE) --

 No deposit bonus casinos are receiving more attention in 2026 as players look for ways to try an online casino before spending their own money. Offers such as 50 no deposit free spins and $200 no deposit bonus 200 free spins real money allow users to test games, review bonus terms, and understand how a casino works before deciding whether to make a deposit.

Thea Energy Accelerates Fusion Energy with Helios Power Plant Digital Twin and AI Surrogate Models in Collaboration with NVIDIA, Synopsys, Argonne National Laboratory, and...

The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission

FLASH GLOBAL LAUNCHES DALLAS CENTER OF EXCELLENCE FOR DISTRIBUTION AND RETURNS OPERATIONS

New Facility, Open July 1st, Supports Continued Growth and Reflects Market Shift Toward Centralized Execution, and Lifecycle-Driven Service Supply chainsPARSIPPANY, N.J., June 8, 2026...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Vision Insurance After Retirement (2026): VSP Vision Care Named Leading Option for Retiree Eye Coverage by Expert Consumers

NEW YORK, June 7, 2026 /PRNewswire/ -- A recent analysis from Expert Consumers highlights VSP® Vision Care as a leading option for vision insurance...

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEvaluation